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ARTICLE
PTPσ inhibitors promote hematopoietic stem
cell regeneration
Yurun Zhang 1,10, Martina Roos2,3,4,10, Heather Himburg2, Christina M. Termini 2, Mamle Quarmyne2,
Michelle Li2, Liman Zhao2, Jenny Kan2, Tiancheng Fang2,5, Xiao Yan2,5, Katherine Pohl2, Emelyne Diers6,
Hyo Jin Gim6, Robert Damoiseaux4,5,7, Julian Whitelegge 8, William McBride4,9, Michael E. Jung6,7 &
John P. Chute 2,3,4,9
Receptor type protein tyrosine phosphatase-sigma (PTPσ) is primarily expressed by adult
neurons and regulates neural regeneration. We recently discovered that PTPσ is also
expressed by hematopoietic stem cells (HSCs). Here, we describe small molecule inhibitors
of PTPσ that promote HSC regeneration in vivo. Systemic administration of the PTPσ inhi-
bitor, DJ001, or its analog, to irradiated mice promotes HSC regeneration, accelerates
hematologic recovery, and improves survival. Similarly, DJ001 administration accelerates
hematologic recovery in mice treated with 5-fluorouracil chemotherapy. DJ001 displays high
specificity for PTPσ and antagonizes PTPσ via unique non-competitive, allosteric binding.
Mechanistically, DJ001 suppresses radiation-induced HSC apoptosis via activation of the
RhoGTPase, RAC1, and induction of BCL-XL. Furthermore, treatment of irradiated human
HSCs with DJ001 promotes the regeneration of human HSCs capable of multilineage in vivo
repopulation. These studies demonstrate the therapeutic potential of selective, small-
molecule PTPσ inhibitors for human hematopoietic regeneration.
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Hematopoietic stem cells (HSCs) express several receptortyrosine kinases (RTKs), including TIE2, fetal liver tyr-osine kinase 3 (FLT3), and vascular endothelial growth
factor receptor 1, which regulate HSC maintenance, proliferation,
and differentiation1–5. RTK signaling is carefully balanced by the
action of intracellular and receptor protein tyrosine phosphatases
(PTPs), which dephosphorylate tyrosine residues on RTKs6,7.
Small-molecule RTK inhibitors have been successfully developed
for clinical practice and are widely utilized in oncology, including
imatinib (BCR-ABL, PDGFR, c-KIT) and other BCR-ABL inhi-
bitors, erlotinib, and gefitinib (epidermal growth factor receptor),
and lapatinib (HER-2)8–10. Therapeutic targeting of PTPs in
clinical practice has progressed more slowly, although the
immunosuppressive agents, cyclosporine and FK506, which
indirectly inhibit a phosphatase, calcineurin, provide evidence
that phosphatase inhibitors can provide important clinical ben-
efits11. Anti-sense oligonucleotides targeting PTP1B also have
been demonstrated to lower blood glucose and increase insulin
sensitivity in Type II diabetes mellitus, and have advanced in
clinical trials12. Challenges to the successful development of PTP
modulators include lack of selectivity, as the active enzymatic
sites of PTPs may be conserved across the PTP family, and cell
permeability, as highly charged anionic phosphate mimetics that
could inhibit PTPs do not cross the cell membrane11,13.
Genetic studies have revealed the function of two intracellular
PTPs, Src-homology-2-domain containing tyrosine phosphatase
2 (SHP2) and phosphatase of regenerating liver 2 (PRL2), in
regulating HSC fate14,15. A gain-of-function mutation in SHP2
promoted HSC cycling and increased HSC-repopulating capacity
and the development of myeloproliferative disease in mice14.
Deletion of PRL2 was associated with a decline in HSC self-
renewal capacity in mice15. However, the functions of receptor
PTPs in regulating HSC fate remain largely unknown. We
recently discovered that pleiotrophin (PTN), a paracrine growth
factor secreted by bone marrow (BM) stromal cells and endo-
thelial cells (ECs), promoted HSC self-renewal and regeneration
via binding and inhibition of receptor PTPζ16–19. PTPζ-deficient
mice display myeloid proliferation, increased numbers of BM
HSCs and progenitors, and increased HSC competitive repopu-
lating capacity17. We subsequently discovered that murine and
human HSCs differentially express another receptor PTP,
PTPσ20. BM cells from PTPσ-deficient mice displayed sig-
nificantly increased competitive repopulating capacity compared
with PTPσ-expressing BM cells and human CB HSCs negatively
selected for PTPσ surface expression demonstrated >10–fold
increased repopulating capacity in NOD/SCID IL2 receptor-γ
chain-deficient (NSG) mice20. Based on these results, we hypo-
thesized that PTPσ negatively regulates HSC self-renewal, and
that pharmacologic inhibition of PTPσ could therapeutically
promote HSC self-renewal. Here we report the development of a
small molecule that selectively inhibits PTPσ via allosteric binding
in BM HSCs. Systemic administration of the PTPσ inhibitor, or
its analog, promoted HSC regeneration, accelerated hematologic
recovery, and improved survival in irradiated mice. Furthermore,
treatment of irradiated, human HSCs with the PTPσ inhibitor
promoted the regeneration of human HSCs capable of multi-
lineage repopulation in NSG mice. These studies reveal a class of
selective PTPσ inhibitors with therapeutic potential to promote
human hematopoietic regeneration.
Results
Development of a selective and allosteric PTPσ inhibitor. We
hypothesized that PTPσ inhibition could promote HSC self-
renewal and sought to develop a small molecule with specific
inhibitory activity against PTPσ. We identified an organic
compound, 6545075 (Chembridge), which was reported to have
binding and inhibitory properties against the catalytic domain of
PTPσ21. We searched a library of 80,000 small molecules in an
attempt to find compounds with similar structural features,
namely 2-arylamino-1-arylpropenones, and identified two addi-
tional compounds, 6515205 and 5483071, which we hypothesized
to have the potential to bind to PTPσ (Fig. 1a). We tested the
inhibitory activity of these three molecules in a direct PTPσ
enzymatic assay (Fig. 1b)22. Compound 5483071 (3071) displayed
strong inhibitory activity against PTPσ, with a half-maximal
inhibitory concentration (IC50) of 1.5 μM, whereas the other
compounds demonstrated lower PTPσ inhibitory activity. We
then prepared a synthetic sample of 3071, named DJ001, and
confirmed the inhibitory effect of DJ001 in the PTPσ enzymatic
assay (Fig. 1c). Importantly, DJ001 displayed no inhibitory
activity against 20 other phosphatases, with only modest inhibi-
tory activity against Protein Phosphatase 5 (Supplementary
Fig. 1a). These data suggested that DJ001 was a highly specific
inhibitor of PTPσ.
We next determined that DJ001 can exist in two different
stereo-isomeric forms, the (Z)- and (E)-isomers (Supplementary
Fig. 2a). The (Z)-isomer displayed significantly increased
binding affinity to both the PTPσ active (catalytic) site and the
allosteric site compared with the (E)-isomer (Supplementary
Fig. 2b, c). Importantly, the (Z)-isomer also demonstrated a
1.3 kcal/mol preference for binding to the allosteric site, located
between domains 1 and 2 of PTPσ, over the catalytic site
(−9.0 kcal/mol vs. −7.7 kcal/mol) (Fig. 1d). Enzyme kinetic
analysis via substrate titration studies demonstrated that DJ001
functions as a non-competitive inhibitor of PTPσ, consistent with
its allosteric binding properties (Fig. 1e). These studies revealed
that DJ001 non-competitively inhibits PTPσ through a unique
mechanism.
PTPσ inhibition promotes hematopoietic regeneration. In
order to determine whether PTPσ inhibition could affect
HSC growth during homeostasis, we cultured non-irradiated BM
CD34−ckit+sca1+lin− (CD34−KSL) HSCs with media (contain-
ing 20 ng/mL Thrombopoietin, 100 ng/mL stem cell factor (SCF),
50 ng/mL Flt3 ligand, TSF) with or without 10–1,000 ng/mL
DJ001 for 7 days. Treatment with DJ001 increased the percentages
and numbers of BM KSL cells in culture compared with control
cultures (Supplementary Fig. 3a). DJ001 treatment also sig-
nificantly increased the numbers of colony forming cells (CFCs) in
3 day culture of BM KSL cells (Supplementary Fig. 3b). Systemic
treatment of adult C57BL/6 mice with 5 mg/kg DJ001, sub-
cutaneously every other day for 30 days, caused no significant
changes in complete blood counts, BM HSC or progenitor cell
content, or BM CFCs compared with vehicle-treated controls
(Supplementary Fig. 3c–e).
In order to determine whether PTPσ inhibition could promote
HSC regeneration following myelosuppressive injury, we irra-
diated BM KSL cells with 300 cGy and placed in TSF media with
and without 1 μg/mL DJ001 for 3 days. DJ001 treatment
increased recovery of BM CFCs and multipotent colony-
forming unit–granulocyte erythroid monocyte megakaryocyte
(CFU-GEMM) colonies compared with control cultures (Fig. 2a
and Supplementary Fig. 4a). In a complementary study, we
irradiated mice bearing constitutive deletion of Ptprs, the gene
that encodes PTPσ (Ptprs−/− mice), with 600 cGy total body
irradiation (TBI). Irradiated Ptprs−/− mice displayed increased
recovery of BM CFCs at day+ 10 compared with irradiated
Ptprs+/+ mice (Fig. 2b). These results suggested that deletion
of Ptprs or PTPσ inhibition comparably promoted hematopoietic
progenitor cell regeneration following irradiation.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11490-5
2 NATURE COMMUNICATIONS |         (2019) 10:3667 | https://doi.org/10.1038/s41467-019-11490-5 | www.nature.com/naturecommunications
In order to determine whether PTPσ inhibition could promote
hematopoietic regeneration in vivo, we irradiated adult C57BL/6
mice with 750 cGy TBI and treated with 5 mg/kg DJ001 or
vehicle subcutaneously every day from day+ 1 to day+ 10. At
day+ 10, DJ001-treated mice displayed more than twofold
increased peripheral blood (PB) white blood cells (WBCs),
neutrophils, and lymphocytes compared with vehicle-treated
controls (Fig. 2c). DJ001 treatment also accelerated the
recovery of BM KSL cells, which are enriched for hematopoietic
stem/progenitor cells (HSPCs), ckit+sca-1−lin− myeloid pro-
genitors, and CFCs following TBI (Fig. 2d, e and Supplementary
Fig. 4b, c). DJ001 treatment did not alter the percentages of BM
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Fig. 1 DJ001 is a non-competitive, allosteric inhibitor of PTPσ. a Chemical structures of compounds 3071, 5205, and 5075. b Concentration-inhibition
curves and IC50 values for 3071, 5205, 5075, and control (DMSO) following incubation with PTPσ (n= 3). c Concentration-inhibition curves and IC50
values for DJ001 and control following incubation with PTPσ (n= 3). d In silico three-dimensional docking of DJ001 (Z isomer) (represented as ball and
stick in yellow color) to the PTPσ allosteric binding site located between domain 1 (green) and domain 2 (blue) of PTPσ. e At left, substrate titration reveals
DJ001 as a non-competitive inhibitor that inhibits substrate catalysis (Vmax), but not substrate binding of PTPσ (constant Km). At right, plots of Km and
Vmax as a function of compound concentration delivered from nonlinear regression in substrate titration. Error bars represent SEM. Source data are
provided as Source Data File
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megakaryocyte erythroid progenitors (MEPs), common myeloid
progenitors (CMPs), granulocyte monocyte progenitors (GMPs),
or PB myeloid, B-cell or T-cell populations, but did cause a
modest increase in percentages of BM common lymphoid
progenitors (CLPs)(Supplementary Fig. 4d, e). Of note, pharma-
cokinetic (PK) analysis of adult C57BL/6 mice treated sub-
cutaneously × 1 with 5 mg/kg DJ001 demonstrated DJ001
concentrations of 10–100 ng/mL in the PB over several hours
post injection (Supplementary Fig. 4f), a concentration range
that promoted BM hematopoietic progenitor cell recovery
in vitro (Supplementary Fig. 3b).
As radiation exposure can cause acute mortality via hemato-
poietic toxicities, we evaluated whether daily administration of
DJ001 from day+ 1 to day+ 10 could increase the survival of
mice following lethal dose TBI. Following 750 cGy TBI, 12 of 29
adult C57BL/6 mice (41%) survived to day+ 40. Conversely, 27
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of 29 irradiated C57BL/6 mice treated with DJ001 (93%)
remained alive and healthy through day+ 40 (P < 0.0001, Log-
rank test, Fig. 2f). Therefore, systemic administration of a PTPσ
inhibitor also improved survival following myeloablative
irradiation.
In order to determine whether DJ001 promoted the
regeneration of HSCs with in vivo repopulating capacity, we
performed competitive repopulation assays using B6.SJL
(CD45.1+) recipient mice and donor BM collected at day+
10 from C57BL/6 (CD45.2+) mice irradiated with 750 cGy TBI
and treated daily with 5 mg/kg DJ001 or vehicle. Recipient mice
transplanted with 5 × 105 BM cells from irradiated control
mice, along with 1 × 105 competitor CD45.1+ BM cells,
displayed declining donor-derived hematopoietic reconstitu-
tion over time following transplant (Fig. 2g). This is consistent
with our prior observations that high-dose TBI depletes HSCs
with long-term repopulating capacity23. In contrast, mice
transplanted with the identical dose of BM cells from irradiated,
DJ001-treated mice displayed significantly increased donor
hematopoietic reconstitution over time compared with controls
(Fig. 2g). Of note, mice transplanted with BM cells from
irradiated, DJ001-treated donor mice displayed significantly
increased percentages of donor CD45.2+Mac1+/Gr1+ myeloid
cells, CD45.2+B220+ B cells, and CD45.2+CD3+ T cells in the
PB at 20 weeks post transplant compared with mice
transplanted with control, irradiated BM cells (Fig. 2h).
In order to determine whether systemic treatment with DJ001
could also promote hematologic recovery following myelosuppres-
sive chemotherapy, we treated adult C57BL/6 mice intravenously
with 250mg/kg 5-fluorouracil (5FU), an antimetabolite chemother-
apeutic that is widely utilized in clinical practice and causes
depression of WBCs and neutrophils24,25. Control mice treated with
5FU displayed leukopenia and neutropenia from day+ 8 through
day+ 14 (Fig. 2i). Mice treated with 5FU followed by 5mg/kg
DJ001 SQ daily through day+ 10 demonstrated significantly
increased PB WBCs and neutrophils at day+ 14.
In order to validate our hypothesis that small-molecule
inhibition of PTPσ could facilitate hematopoietic regeneration
following myelotoxicity, we designed and synthesized more than
50 structural analogs of DJ001. One of them, DJ009, with a 3,5-
difluorophenyl ring substituted for the 3-nitrophenyl unit of
DJ001 (Supplementary Fig. 5a), strongly inhibited PTPσ activity
in vitro (Supplementary Fig. 5b). When C57BL/6 mice were
irradiated with 750 cGy TBI and subsequently treated daily with
5 mg/kg DJ009 for 10 days, we observed a significant increase in
PB WBCs, neutrophils and lymphocytes, BM KSL cells, and CFCs
in response to DJ009 treatment (Supplementary Fig. 5c–e).
Consistent with these findings, DJ009 treatment also significantly
increased survival of irradiated C57BL/6 mice (Supplementary
Fig. 5f). These results provided further evidence that small-
molecule PTPσ inhibitors can promote hematopoietic regenera-
tion in vivo following myelosuppression.
PTPσ inhibitor effects on cytokine levels. Although our in vitro
studies suggest that PTPσ inhibition directly promotes HSPC
regeneration, it is also possible that treatment with DJ001 may
have caused indirect effects via alterations in the production of
cytokines by hematopoietic progenitor cells or their micro-
environment. Indeed, hematopoietic progenitor cells have been
shown to secrete several inflammatory cytokines in response to
lipopolysaccharide and Pam3CSK4, a Toll-like receptor 2
ligand26. In order to address this, we measured 38 cytokines in
cultures of non-irradiated and irradiated BM KSL cells treated
with and without DJ001, and also measured the identical cyto-
kines in the BM of non-irradiated C57BL/6 mice and irradiated
C57BL/6 mice at day+ 5 following treatment with DJ001 or
vehicle. At 12 h following 300 cGy irradiation of BM KSL cells
in vitro, we detected increased levels of lipopolysaccharide-
induced CXC chemokine (LIX), macrophage inflammatory
protein-1α (MIP-1α) and MIP-1β, and no other changes; DJ001
treatment decreased LIX levels following irradiation but had no
effects on any other cytokines in vitro (Supplementary Fig. 6a, b).
At day+ 5 following 750 cGy TBI in C57BL/6 mice, we detected
decreased levels of LIX and CXCL12 in the BM and increased
levels of SCF and PTN. DJ001 treatment had no effects on
cytokine levels in non-irradiated mice, but caused a modest
increase in CXCL12 levels and a decrease in PTN levels in the BM
of irradiated mice compared with irradiated, vehicle-treated mice
(Supplementary Fig. 6c, d).
PTPσ inhibition promotes HSC survival via induction of
RAC1. The mechanisms through which PTPσ regulates cellular
functions are not well understood27. In a yeast-two-hybrid sys-
tem, PTPσ was shown to dephosphorylate p250GAP, a RhoGT-
Pase that attenuates RAC1 activity27. In the presence of PTPσ,
p250GAP activity increased and RAC1 activity declined27. Here
we tested whether PTPσ inhibition with DJ001 could alter
p250GAP phosphorylation and RAC1 activation in primary
hematopoietic progenitor cells. For this purpose, we developed an
enzyme-linked immunosorbent sandwich enzyme-linked immu-
nosorbent assay (ELISA) employing immunoglobulin A capture
of p250GAP (Supplementary Fig. 7a). Treatment with 1 µg/mL
DJ001 significantly increased phosphorylation of p250GAP in
BM lin− cells (Fig. 3a). Furthermore, DJ001 treatment sig-
nificantly decreased co-localization of PTPσ and p250GAP in BM
KSL cells, as measured by proximity ligation assay (PLA; Fig. 3b).
DJ001 treatment also caused a rapid increase in RAC1-GTP levels
in BM KSL cells (Fig. 3c). Importantly, DJ001 treatment did not
alter the activation of other RhoGTPases, CDC42, or RhoA, in
BM lin− cells, suggesting that CDC42 and RhoA did not con-
tribute to DJ001-mediated effects in hematopoietic progenitor
cells (Supplementary Fig. 7b). Therefore, PTPσ repressed RAC1
activation in HSPCs via regulation of p250GAP and DJ001 pro-
moted RAC1 activation via inhibition of PTPσ and p250GAP
function. Of note, DJ001 treatment of BM KSL cells from
Fig. 2 PTPσ inhibition promotes hematopoietic regeneration. a Mean numbers of CFCs from BM KSL cells following 300 cGy irradiation and culture for
3 days in TSF media ± DJ001 (n= 12). b Mean numbers of BM CFCs in Ptprs+/+ and Ptprs−/− mice at day+ 10 following 600 cGy TBI (n= 12). c Mean
numbers of PB WBCs, neutrophils (NEU), and lymphocytes (LYMPH) in mice at day+ 10 following 750 cGy and treatment with DJ001 or 10% DMSO
(vehicle) (n= 10). d Representative flow cytometric analysis of percentages of KSL cells and c-kit+sca-1− progenitor cells at day+ 10 post 750 cGy in the
treatment groups shown. e Mean percentages and numbers of BM KSL cells and c-kit+sca-1− cells at day+ 10 post 750 cGy (n= 9). f Percent survival of
mice after 750 cGy and treatment with DJ001 (27/29 alive) or vehicle (12/29 alive); Log-rank test. g Mean percentages of donor CD45.2+ cells in the PB
of CD45.1+ recipient mice over time following transplantation of 5 × 105 BM cells from CD45.2+ mice at day+ 10 following 750 cGy TBI and treatment
with DJ001 or vehicle, along with 1 × 105 CD45.1+ BM competitor cells (n= 18–21/group). hMean percentages of total donor CD45.2+ cells and CD45.2+
Mac1+Gr1+ myeloid cells, CD45.2+B220+ B cells, and CD45.2+CD3+ T cells in the PB of recipient mice at 20 weeks post transplantation (n= 18/group).
i Mean numbers of PB WBCs and NEU counts in mice at day+ 0 (pre-5FU), + 8, + 11, and + 14 following 5FU treatment (n= 4–7/group). Error bars
represent SEM. Source data are provided as Source Data File. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
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Ptprs−/− mice caused no change in RAC1-GTP levels, suggesting
that DJ001-mediated activation of RAC1 occurred specifically via
PTPσ (Fig. 3c). DJ009 also did not induce RAC1 activation in BM
cells from Ptprs−/− mice, suggesting similar selectivity of DJ009
for PTPσ (Supplementary Fig. 7c). Treatment of BM KSL cells
with DJ001 increased phosphorylation of p21-activated kinase 1
(PAK1), a substrate of RAC1, and concomitant treatment with
the RAC inhibitor, EHT186428, abrogated DJ001-mediated
phosphorylation of PAK1 (Fig. 3d).
Ionizing radiation causes HSC death via direct DNA damage,
generation of reactive oxygen species, and induction of pro-
apoptotic mediators25,29. DJ001 treatment significantly decreased
the percentage of apoptotic BM KSL cells in C57BL/6 mice at 24 h
following 500 cGy TBI compared with vehicle-treated controls
(Fig. 3e). Administration of the RAC inhibitor, EHT1864,
abrogated DJ001-mediated anti-apoptotic effects on BM KSL
cells in irradiated mice (Fig. 3e). Similarly, treatment with
EHT1864 inhibited DJ001-mediated CFC generation from BM
KSL cells irradiated with 300 cGy in vitro (Supplementary
Fig. 7d). Systemic administration of EHT1864 also completely
blocked DJ001-mediated increase in survival of irradiated mice
(Fig. 3f). These results suggested that DJ001-mediated anti-
apoptotic and regenerative effects on BM HSPCs were dependent
on RAC pathway activation.
RhoGTPases such as RAC1 can affect multiple signaling
pathways that regulate cell survival30–34, so we next measured the
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effect of DJ001 treatment on the expression of pro- and anti-
apoptotic genes in irradiated KSL cells (Fig. 3g). DJ001 treatment
had no effect on the expression of pro-apoptotic mediators, Bim,
Bax, p53 upregulated modulator of apoptosis (Puma), or the anti-
apoptotic gene, Bcl2, in BM KSL cells (Table 1). However, DJ001
treatment increased the expression of Mcl-1 and Bcl2 like 1
(Bcl2l1), which encodes the anti-apoptotic protein, BCL-XL, as
well as BCL-XL protein levels in irradiated BM KSL cells (Fig. 3g,
h). RAC inhibition blocked the increase in BCL-XL protein levels
in irradiated BM KSL cells in response to DJ001, suggesting that
DJ001-mediated induction of Bcl2l1 expression was RAC pathway
dependent (Fig. 3h). In order to confirm that DJ001-mediated
effects on irradiated HSPCs were dependent on RAC1 and BCL-
XL, we transduced BM KSL cells separately with lentiviral short
hairpin RNAs (shRNAs) targeting Rac1 or Bcl2l1 and measured
hematopoietic progenitor cell recovery following 300 cGy irradia-
tion. Silencing of either Rac1 or Bcl2l1 blocked DJ001-mediated
recovery of hematopoietic progenitor cells from irradiated BM
KSL cells (Fig. 3i). Taken together, these results suggested that
DJ001-mediated HSPC recovery after irradiation was dependent
on RAC1 and BCL-XL.
RAC1 has been shown to activate ERK1/2 signaling via PAK1-
and PAK2-mediated phosphorylation of MEK1 to facilitate the
formation of the Raf/MEK/ERK complex35. Consistent with this,
DJ001 treatment induced ERK1/2 phosphorylation in irradiated
BM KSL cells, which was suppressed by RAC inhibition
(Supplementary Fig. 7e). Furthermore, treatment with the
ERK1/2 inhibitor, BVD523, blocked DJ001-mediated increase in
BCL-XL protein levels in BM KSL cells and abrogated
hematopoietic progenitor cell recovery following irradiation
(Supplementary Fig. 7f, g). These data suggested that DJ001-
mediated induction of BCL-XL in HSPCs was dependent on
ERK1/2, downstream of RAC pathway activation.
PTPσ inhibition promotes HSPC proliferation via Cdk2.
Hematologic recovery following myelosuppressive irradiation
requires not only survival of long-term HSCs but also the pro-
liferation of HSCs and progenitor cells to facilitate regeneration of
essential blood elements. DJ001 treatment did not alter the cell
cycle status of non-irradiated BM KSL cells in culture with
thrombopoietin, SCF, and Flt3 ligand (Supplementary Fig. 7h).
However, DJ001 treatment of BM KSL cells for 36 h following
300 cGy irradiation significantly increased the percentage of KSL
cells in G2/S/M phase compared with control, irradiated KSL cells
(Fig. 4a). Evaluation of the expression of cell cycle regulatory
genes revealed that DJ001 treatment did not alter the expression
of cyclin-dependent kinase 4 (Cdk4), Cdk6, Cdkn1a, Cdkn1b,
Cyclin D1, or Cyclin D2 in irradiated BM KSL cells (Fig. 4b and
Table 1). However, DJ001 treatment significantly increased the
expression of Cdk2 and Cyclin E in irradiated KSL cells. Trans-
duction of BM KSL cells with Rac1-shRNA blocked DJ001-
mediated transcription of Cdk2 and Cyclin E, suggesting that
DJ001-induced expression of Cdk2 and Cyclin E in KSL cells was
RAC1 dependent (Fig. 4c). Furthermore, treatment of irradiated
BM KSL cells with SU9516, a specific CDK2 inhibitor, or the RAC
inhibitor, EHT1864, suppressed DJ001-mediated induction of cell
cycle progression in BM KSL cells following irradiation (Fig. 4d).
These results suggested that DJ001-mediated HSC cell cycle
progression following irradiation was dependent on RAC path-
way activation and CDK2.
In order to test whether systemic treatment with DJ001 altered
HSC proliferation in vivo following irradiation, we measured
BrdU incorporation in BM KSL cells of C57BL/6 mice at day+ 10
Fig. 3 DJ001 promotes HSC regeneration via RAC1 activation and induction of BCL-XL. a %p250GAP phospho-tyrosine (pTyr) in BM lin− cells cultured
± DJ001 (media, n= 10; DJ001, n= 7). b At left, representative images of PLA in BM KSL cells treated ± DJ001. Red=DsRed+, PTPσ-p250GAP complex;
blue=DAPI, original magnification ×63, scale bars= 10 µm). At right, numbers of DsRed+ KSL cells in each condition (n= 48, control; n= 36, DJ001). c%
RAC1-GTP+ KSL cells from Ptprs+/+ and Ptprs−/− mice treated ± DJ001 (n= 5). Two-way ANOVA with Sidak’s multiple comparison test. d Percentages of
p-PAK1+ KSL cells following treatment with media alone, 1 μg/mL DJ001, or DJ001+ 6 μg/mL EHT1864 (n= 5). One-way ANOVA with Tukey’s multiple
comparison test. e At left, Annexin V/7AAD staining of BM KSL cells from mice at 24 h post 500 cGy and treatment with vehicle, 5 mg/kg DJ001,
DJ001+ 40mg/kg EHT1864, or EHT1864 alone. Numbers represent percentages in each gate. At right, %Annexin+7AAD− BM KSL cells (media and
DJ001, n= 9; DJ001+ EHT1864, n= 7; EHT1864, n= 4). f Percent survival of mice following 750 cGy and 10-day treatment with DJ001 (11/15 alive),
vehicle (4/15 alive), or DJ001+ EHT1864 (2/15 alive; Log-rank test). g Fold changes (2−ΔΔCt) of gene expression in BM KSL cells at 12 h post 300 cGy and
treatment with or without DJ001 (n= 3–6/group). Two-way ANOVA with Sidak’s multiple comparison test. h At left, BCL-XL protein levels in non-
irradiated BM KSL cells (red), 300 cGy-irradiated KSL cells in media alone (black) or treated with DJ001 (blue) or DJ001+ EHT1864 (gray). At right, %
BCL-XL+ KSL cells (n= 6). One-way ANOVA with Tukey’s multiple comparison test. i CFCs from BM KSL cells at 48 h following 300 cGy and culture with
and without DJ001, and with and without shRac1 or shBcl2l1 (n= 3–9/group). Two-way ANOVA with Sidak’s multiple comparison test. Error bars represent
SEM. Source data are provided as Source Data File. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
Table 1 Primers used for mouse gene detection
Target mRNA Sequence 5′–3′
Gapdh Fw TGGATTTGGACGCATTGGTC
Gapdh Rv TTGCACTGGTACGTGTTGAT
Bcl2l1 Fw GACAAGGAGATGCAGGTATTGG
Bcl2l1 Rv TCCCGTAGAGATCCACAAAAG
Bax Fw TGAAGACAGGGGCCTTTTTG
Bax Rv AATTCGCCGGAGACACTCG
Bcl2 Fw TGAGTACCTGAACCGGCATCT
Bcl2 Rv GCATCCCAGCCTCCGTTAT
Bim Fw CGGATCGGAGACGAGTTCA
Bim Rv TTCCAGCCTCGCGGTAATCA
Puma Fw AGCAGCACTTAGAGTCGCC
Puma Rv CCTGGGTAAGGGGAGGAGT
Mcl-1 Fw AAAGGCGGCTGCATAAGTC
Mcl-1 Rv TGGCGGTATAGGTCGTCCTC
Cdk2 Fw CCTGCTTATCAATGCAGAGGG
Cdk2 Rv TGCGGGTCACCATTTCAGC
Cdk4 Fw ATGGCTGCCACTCGATATGAA
Cdk4 Rv TCCTCCATTAGGAACTCTCACAC
Cdk6 Fw GGCGTACCCACAGAAACCATA
Cdk6 Rv AGGTAAGGGCCATCTGAAAACT
Cdkn1a Fw CCTGGTGATGTCCGACCTG
Cdkn1a Rv CCATGAGCGCATCGCAATC
Cdkn1b Fw TCAAACGTGAGAGTGTCTAACG
Cdkn1b Rv CCGGGCCGAAGAGATTTCTG
Cyclin E Fw GCCAGCCTTGGGACAATAATG
Cyclin E Rv CTTGCACGTTGAGTTTGGGT
Rac1 Fw GAGACGGAGCTGTTGGTAAAA
Rac1 Rv ATAGGCCCAGATTCACTGGTT
Cyclin D1 Fw GCGTACCCTGACACCAATCTC
Cyclin D1 Rv CTCCTCTTCGCACTTCTGCTC
Cyclin D2 Fw GAGTGGGAACTGGTAGTGTTG
Cyclin D2 Rv CGCACAGAGCGATGAAGGT
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Fig. 4 DJ001 promotes HSC proliferation via induction of CDK2. a At left, representative cell cycle analysis of BM KSL cells at 36 h following 300 cGy and
culture with media ± 1 μg/mL DJ001. At right, mean percentages of KSL cells in G0 (Ki67−7AAD−), G1 (Ki67+7AAD−) and G2/S/M phase (Ki67+7AAD+)
are shown (n= 7). b Fold changes (2−ΔΔCt) of cell cycle regulatory gene expression in KSL cells at 36 h following 300 cGy and culture with media ± DJ001
(n= 3). Gene transcript changes are normalized to Gapdh and media treatment. c Fold changes (2−ΔΔCt) of Cdk2 and Cyclin E expression in BM lin− cells in
response to DJ001 at 48 h after 300 cGy, with and without Rac1-shRNA treatment (n= 3–5). d Top panel shows representative cell cycle analysis of KSL
cells at 36 h following 300 cGy and culture with media ± 1 µg/mL DJ001, DJ001 ± 6 µg/mL EHT1864, and DJ001 ± 240 ng/mL CDK2 inhibitor SU9516.
Bottom panel shows the percentages of BM cells in G0, G1, and G2/S/M phase for each condition (media, n= 6; DJ001 and DJ001+ SU9516 groups, n= 5;
DJ001+ EHT1864, n= 8). Two-way ANOVA with Sidak’s multiple comparison test for a–c. One-way ANOVA with Tukey’s multiple comparison test for
d. Source data are provided as Source Data File. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11490-5
8 NATURE COMMUNICATIONS |         (2019) 10:3667 | https://doi.org/10.1038/s41467-019-11490-5 | www.nature.com/naturecommunications
following 750 cGy TBI and treatment with or without DJ001. BM
KSL cells from DJ001-treated mice displayed increased bromo-
deoxyuridine (BrdU) incorporation compared with irradiated,
vehicle-treated controls (Supplementary Fig. 7i). In order to
determine whether DJ001 treatment caused durable effects on
HSC cell cycle status, we measured BrdU incorporation in donor
CD45.2+ cells in recipient CD45.1+mice at day+ 7 and day+ 21
following competitive transplantation. Of note, donor cells were
collected from the BM of CD45.2+ mice at day+ 10 following
750 cGy TBI and daily treatment with DJ001 or vehicle, and then
transplanted into lethally irradiated CD45.1+ recipient mice, as
described in Fig. 2. We detected no difference in BrdU
incorporation between donor CD45.2+ cells from either the
DJ001- or vehicle-treatment groups at these time points in
recipient mice (Supplementary Fig. 7j).
Deletion of Rac1 has been shown to decrease the homing,
engraftment, and niche localization of hematopoietic stem and
progenitor cells30,31,36. Therefore, it is possible that systemic
treatment of mice with DJ001 altered Rac1-mediated migration
and localization of endogenous HSCs in supportive BM niches,
thereby facilitating hematopoietic regeneration in vivo. We
observed that DJ001 treatment did not alter the in vitro migration
of BM KSL cells through EC monolayers and had no effect on
homing of transplanted BM ckit+lin− cells at 18 h in irradiated
C57BL/6 mice (Supplementary Fig. 8a, b).
PTPσ inhibition promotes human HSC regeneration. As DJ001
promoted murine hematopoietic regeneration following myelo-
suppression, we sought to determine whether DJ001 could also
accelerate human HSC regeneration. Irradiation of human BM
CD34+ cells with 300 cGy in vitro caused a significant loss of
CD34+CD38− cells, which are enriched for human HSCs37, at 36
h after irradiation (Fig. 5a). Treatment with 5 µg/mL DJ001
increased the recovery of viable human BM CD34+CD38− cells
following irradiation (Fig. 5a). DJ001 also increased the recovery
of multipotent CFU-GEMMs at 72 h following irradiation
of human BM CD34+ cells (Fig. 5b). Mechanistically, DJ001
treatment decreased radiation-induced apoptosis of human
CD34+CD38− cells following irradiation (Fig. 5c). RAC inhibi-
tion blocked DJ001-mediated survival of irradiated human
CD34+CD38− cells, suggesting that DJ001-mediated anti-apop-
totic effects on human HSCs were RAC pathway dependent
(Fig. 5c). As we observed in our murine studies, DJ001 treatment
increased the expression of the pro-survival genes, BCL2L1 and
MCL-1, in irradiated human CD34+ cells (Fig. 5d and Table 2).
In order to determine whether PTPσ inhibition could promote
the recovery of human HSCs with in vivo repopulating capacity,
we irradiated human BM CD34+ cells with 300 cGy, cultured
with TSF media with or without DJ001 for 36 h, and transplanted
the progeny into NSG mice to assess human hematopoietic
engraftment over time (Fig. 5e). Mice transplanted with
irradiated, DJ001-treated BM CD34+ cells displayed substantially
increased engraftment of human CD45+ cells, CD19+ B cells,
CD33+ myeloid cells, and CD3+ T cells at 12 weeks post
transplant compared with mice transplanted with equal doses of
irradiated, control BM CD34+ cells (Fig. 5f, g). Therefore, PTPσ
inhibition promoted the recovery of human HSCs with multi-
lineage repopulating capacity following irradiation.
Discussion
PTPs have been recognized as important potential drug targets
due to their involvement in the pathogenesis of numerous dis-
eases38,39. However, active site-directed PTP inhibitors frequently
lack target specificity due to the high degree of homology between
PTP active sites40,41. Negatively charged phospho-tyrosine
mimetics also have poor bioavailability, as they are typically cell
impermeable40. These barriers have hindered the development of
PTP active site inhibitors for clinical use. A recent analysis of
non-receptor and receptor PTPs for “druggability” suggested that
the majority of PTPs were poor drug targets due to the hydro-
philic or shallow nature of their catalytic pockets38. As an alter-
native strategy, allosteric inhibitors have been described for
specific PTPs, including selective inhibitors for dual specificity
phosphatase 6 and the SHP240,42. A small molecule, allosteric
inhibitor of SHP2 was recently shown to inhibit RTK-driven
human cancer growth in xenograft models43. Here we describe a
small molecule that non-competitively inhibits PTPσ via allosteric
binding and is highly selective for PTPσ. Based on these unique
properties, we propose that DJ001, and DJ001 structural homo-
logs, are compelling candidates for therapeutic development.
A large number of patients with cancer require myelosup-
pressive chemotherapy and/or radiotherapy in the treatment of
their disease44. Hematopoietic toxicities occur commonly in such
patients, resulting in hospitalizations, delays in curative therapy,
and potentially life-threatening infectious complications45.
Depletion of BM HSCs and progenitor cells, which occurs fol-
lowing repeated cycles of cytotoxic chemotherapy, contributes to
prolonged myelosuppression in such patients46. Therapies that
promote HSC and progenitor cell regeneration could lessen the
complications of myelosuppression and facilitate the timely
completion of potentially curative chemotherapy. However, the
mechanisms that govern HSC regeneration are poorly understood
and this gap in knowledge has impeded the development of
targeted therapies to drive human hematopoietic regeneration.
Here we demonstrate that systemic administration of a small
molecule inhibitor of PTPσ accelerated hematopoietic regenera-
tion in mice following irradiation or chemotherapy. Furthermore,
PTPσ inhibition promoted the recovery of human hematopoiesis
and human HSCs with long-term repopulating capacity in NSG
mice following irradiation. Taken together, these results suggest
the therapeutic potential for a small-molecule PTPσ inhibitor to
accelerate hematologic recovery in cancer patients receiving
myelosuppressive chemotherapy or radiotherapy.
Our in vitro studies of non-irradiated BM CD34−KSL cells
suggested the potential for DJ001 or DJ001 analogs to promote
hematopoietic progenitor cell expansion; however, in vivo
administration of DJ001 3 days per week for 4 weeks caused no
expansion of HSCs, progenitors, or mature blood counts in non-
irradiated mice. The absence of effect in non-irradiated mice may
have occurred due to insufficient concentrations of DJ001
achieved in the BM of non-irradiated mice following the cho-
sen treatment schedule or possibly due to indirect effects of
systemically administered DJ001 on cytokines or chemokines in
the BM that counteracted direct effects on HSCs. Our analysis of
the BM of non-irradiated mice revealed no significant changes in
cytokine or chemokine levels in response to DJ001 treatment.
Following TBI, DJ001 treatment was associated with modest
changes in concentrations of the HSC growth factors, CXCL12
and PTN, in the BM compared with controls. These results
suggest that DJ001 promotes HSC regeneration primarily via
direct effects on HSCs; however, indirect effects of DJ001 via
undiscovered mechanisms cannot be not excluded.
PTPσ and related receptors within the leukocyte common anti-
gen-related (LAR) subfamily of PTPs are expressed by neurons
and act as receptors for heparan sulfate proteoglycans47–50. In
the developing nervous system, PTPσ regulates axon guidance
and synapse formation47–52. PTPσ also serves as a receptor for
inhibitory glycosylated side chains of chondroitin sulfate pro-
teoglycans (CSPGs)47,53–55. CSPGs, which are enriched in the
extracellular matrix surrounding injured nerves, inhibit axon
regeneration following spinal cord injury6,7. Genetic deletion of
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PTPσ promoted axon regeneration in a model of spinal cord
injury, suggesting that PTPσ may be a therapeutic target to
enhance nerve regeneration47. Subsequently, systemic delivery of
a peptide-mimetic of the PTPσ wedge domain was reported to
relieve CSPG-mediated inhibition and restore serotonergic
innervation of the spinal cord in rats53. In a model of myocardial
infarction, genetic deletion or injection of a PTPσ intracellular
peptide beginning 3 days after injury promoted sympathetic
innervation in the area of myocardial scar56. Here we
demonstrate that systemic delivery of a small-molecule PTPσ
inhibitor drives HSC regeneration and hematopoietic recon-
stitution in vivo following myelosuppression. The combined
benefits of PTPσ inhibition on hematopoietic and neural regen-
eration suggest an important role for PTPσ in regulating adult
somatic cell regeneration.
Mechanistically, PTPσ inhibition suppressed radiation-induced
apoptosis of murine and human HSCs. Downregulation of LAR
protein, which, along with PTPσ and PTPδ, comprises the Type
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IIa receptor PTPs, has similarly been shown to have pro-survival
effects on neurons in the setting of serum deprivation57,58. Our
results suggest that PTPσ inhibition promotes HSC survival fol-
lowing irradiation via RAC pathway activation and induction of
BCL-XL in HSCs. Treatment with the PTPσ inhibitor, DJ001,
uncoupled PTPσ binding to p250GAP, causing RAC1 activation
in primary BM HSCs, without affecting other RhoGTPases,
CDC42 and RhoA. Deletion of Rac1 in the hematopoietic com-
partment of mice has been shown to cause decreased HSPC
engraftment, homing, and niche localization30,31,36, whereas
expression of a dominant-negative Rac2 increased HSPC apop-
tosis36,59. RAC1 has also been shown to inhibit apoptosis of
irradiated breast cancer cells, epithelial cells, and T cells via
induction of BCL-XL, MCL-1, and other BCL-2-like
proteins32,60–62. Here, PTPσ inhibition with DJ001 increased
the expression and protein levels of BCL-XL in HSCs and sup-
pressed HSC apoptosis following irradiation, dependent upon
RAC pathway and ERK1/2 activation. These results suggest that
RAC pathway activation and induction of BCL-XL regulate HSC
survival in response to PTPσ inhibition.
In addition to regulation of HSC survival, our data suggest that
DJ001 promoted early HSPC proliferation compared with irra-
diated, control HSCs. Further, DJ001-mediated HSC cell cycle
progression was dependent on RAC pathway activation and
induction of CDK2. These findings are consistent with the
observations by Gu et al.30, who showed that Rac1−/− HSPCs
displayed decreased entry into G2/S/M phase in response to SCF.
As PTPσ regulates the phosphorylation of several kinases and the
RAC pathway regulates multiple pathways, PTPσ inhibition may
have altered the expression of other effectors that regulate HSC
proliferation beyond CDK2. However, we did not observe any
durable effect of DJ001 treatment on the proliferative potential of
HSCs or their progeny based on BrdU incorporation analysis of
engrafted donor CD45.2+ cells over time following transplanta-
tion into recipient CD45.1+ mice. It is therefore perhaps more
likely that the anti-apoptotic effects of systemic DJ001 treatment
on HSCs in irradiated mice contributed to the increase in
recovery of phenotypic HSPCs as well as HSCs with in vivo
repopulating capacity. It is also possible that DJ001 treatment
favorably affected HSC transcriptional programs that regulate
myeloid and lymphoid cell differentiation and HSC repopulating
potential63.
The paucity of therapeutics capable of accelerating HSC
regeneration and hematopoietic reconstitution in myelosuppressed
patients highlights an unmet medical need. Here we describe a
class of selective, allosteric PTPσ inhibitors that promote the
regeneration of murine and human HSCs capable of long-term
hematopoietic reconstitution. Our results provide the mechanistic
foundation for the development of selective PTPσ inhibitors to
promote hematopoietic regeneration in patients receiving myelo-
suppressive chemotherapy, radiotherapy, and those undergoing
myeloablative hematopoietic cell transplantation.
Methods
Animal models. All animal procedures were performed in accordance with animal
use protocols approved by the UCLA Animal Research Committee (Approval
Number 2014-021-13M). Ptprs−/− mice were provided by Dr Michel Tremblay
(McGill University). C57BL/6 mice, B6.SJL mice, and NOD.Cg-PrkdcscidIl2rgtm1Wjl/
SzJ (NSG) mice between 8 and 12 weeks old were obtained from the Jackson
Laboratory.
Synthesis of DJ001. A mixture of 1-phenylprop-2-yn-1-one* (0.303 g, 2.3 mmol),
3-nitroaniline (0.427 g, 3.0 mmol), and copper (I) iodide (0.078 g, 0.4 mmol) in
dimethylformamide (6 mL) and water (60 μL) was stirred at 85 °C for 16 h. After
16 h, the reaction mixture was allowed to cool down to 21 °C and was diluted with
water (50 mL), and extracted with ethyl acetate (3 × 50 mL). The combined organic
layer was washed with NH4Cl/NH3 (1:1 v/v, 3 × 20 mL) and brine (30 mL), dried
over MgSO4, filtered, and concentrated under reduced pressure. The crude residue
was purified by column chromatography (n-hexane/ethyl acetate= 20:1) to
obtain (Z)-3-((3-nitrophenyl)amino)-1-phenylprop-2-en-1-one (DJ001,140 mg,
0.52 mmol, 23%) as a yellow powder. 1H NMR (400MHz, CDCl3) δ 12.26 (d, NH,
J= 11.6 Hz), 7.96–7.91 (m, 3 H), 7.90 (ddd, 1 H, J= 8.0, 2.0, 0.8 Hz), 7.56–7.46
(m, 5 H), 7.37 (ddd, 1 H, J= 8.0, 2.4, 0.8 Hz), 6.16 (d, 1 H, J= 8.0 Hz); 13C NMR
(100MHz, CDCl3) δ 191.8, 149.4, 143.4, 141.6, 138.6, 132.2, 130.6, 128.6, 127.5,
122.3, 117.8, 110.0, 95.7. High resolution mass spectrometry (HRMS) m/z calcu-
lated for C15H13N2O3 [M+H]+ 269.0904, found 269.0921. *1-Phenylprop-2-yn-
1-one was prepared by oxidation of 1-phenylprop-2-yn-1-ol in a two-step proce-
dure from benzaldehyde and trimethylsilylacetylene by a known method64.
Synthesis of DJ009. (Z)-3-((3,5-difluorophenyl)amino)-1-phenylprop-2-en-1-
one (DJ009) was prepared by the same procedure using 3,5-difluoroaniline. 1H
NMR (400MHz, CDCl3) δ (p.p.m.): 12.0 (d, J= 11.7 Hz, 1 H), 7.94 (dt, J= 6.9, 1.6
Hz, 2 H), 7.55–7.50 (m, 1 H), 7.48–7.45 (m, 2 H), 7.38 (dd, J= 11.7, 8.2 Hz, 1 H),
6.64–6.57 (m, 2 H), 6.54–6.47 (m, 1 H), 6.09 (d, J= 8.2 Hz, 1 H); 13C NMR (100
MHz, CDCl3) δ (p.p.m.): 191.7, 164.0 (dd, J= 249, 15 Hz), 143.5, 142.8 (t, J= 13
Hz), 138.7, 132.1, 128.6, 127.5, 99.3 (dd, J= 20, 8 Hz), 98.5 (t, J= 26 Hz), 95.3; 19F
NMR (CDCl3, 376 MHz) δ (p.p.m.): −107.9. HRMS m/z calcd. for C15H12F2NO
[M+H]+ 260.0881, found 260.0866.
Phosphatase assay. The two intracellular catalytic domains (D1 and D2) of Ptprs
were cloned into a pET28a vector, overexpressed in Escherichia coli BL21 and
purified65. Enzymatic activity of PTPσ was assayed using a modified version of the
Malachite Green Assay66 and the Tyrosine Phosphatase Assay Kit (Promega
Corporation). Unless stated otherwise, standard assays were carried out using
50 nM PTPσ protein in 1× Buffer (10 mM Tris, 5 mM MgCl2, 10 mM NaCl, 0.02%
Tween) and Tyr Phosphopeptide as substrate (200 μM for Fig. 1b, c, 50–1200 μM
in Fig. 1c). Purified catalytic domain 1 and domain 2 of PTPσ were pre-incubated
Fig. 5 DJ001 promotes human HSC regeneration following irradiation. a At left, representative flow cytometric analysis of CD34+CD38- cells at 36 h after
300 cGy irradiation of BM CD34+ cells and culture with media ± 1 µg/mL DJ001. At right, mean percentages and numbers of CD34+CD38− cells in
each group (Day 0, n= 6; media, DJ001, n= 10). One-way ANOVA with Tukey’s multiple comparison test. b Numbers of CFU-GEMMs within cultures of
CD34+ cells at 72 h after 300 cGy and culture with media ± DJ001 (n= 6). c At left, representative flow cytometric analysis of Annexin V/7AAD staining
of CD34+ cells at 24 h after 300 cGy and culture with media ± DJ001 ± EHT1864. At right, percentages of live and apoptotic CD34+CD38− cells in each
condition (media and DJ001, n= 10; DJ001+ EHT1864, n= 5). One-way ANOVA with Tukey’s multiple comparison test. d Fold changes (2−ΔΔCt) in
BCL2L1 and MCL-1 gene expression in CD34+CD38− cells at 12 h after 300 cGy in media ± DJ001 (n= 3). Gene transcript changes were normalized to
GAPDH and media treatment. Two-way ANOVA with Sidak’s multiple comparison test. e Schematic representation of NSG mice transplantation assay
using the progeny of human BM CD34+ cells irradiated with 300 cGy and treated with or without DJ001 × 36 h. f Representative flow cytometric analysis
of human CD45+ cells, human CD34+ cells, human CD19+ B cells, human CD33+ myeloid cells, and human CD3+ T cells engraftment in the BM of NSG
mice at 12 weeks post transplantation. g Percent engraftment of human hematopoietic cell subsets in the BM of NSG mice at 12 weeks post transplantation
(n= 11–12/group). Source data are provided as Source Data File. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
Table 2 Primers used for human gene detection
Target mRNA Sequence 5′–3′
hGAPDH Fw CCTGCACCACCAACTGCTTA
hGAPDH Rv GGCCATCCACAGTCTTCTGAG
hBCL2L1 Fw GACTGAATCGGAGATGGAGACC
hBCL2L1 Rv GCAGTTCAAACTCGTCGCCT
hMCL-1 Fw TGCTTCGGAAACTGGACATCA
hMCL-1 Rv TAGCCACAAAGGCACCAAAAG
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with test compounds 3071, 5205, 5075, or control for 15min in a 96-well plate before
the addition of Tyr Phosphopeptide (DADE(pY)LIPQQG). For IC50 determination,
rates normalized relative to uninhibited controls (dimethyl sulfoxide (DMSO)) were
plotted against compound concentration and fitted using a four-parameter nonlinear
regression curve fit ((y= [(A−D) (1+ {xC− 1}B)− 1]+D) (Prism 6.0, Graphpad
Software). For mechanism studies and determination of the enyzme’s Km and Vmax,
data were analyzed using a nonlinear regression fit according to the classical
Michaelis–Menten kinetics model, Y=Vmax*X/(Km+X) (Prism 6.0, Graphpad
Software).
Phosphatase Profiler screen. Compound DJ001 was evaluated in a Phosphata-
seProfiler™ screen at 10 μM and 1 μM (2.7 μg/mL and 0.27 μg/mL) concentrations
at Eurofins Pharma Discovery Services UK (Study number UK022-0004033)
against a panel of 21 Phosphatases. In each experiment, the respective reference
antagonist/agonist was tested directly with DJ001 and the data were compared with
historical values determined at Eurofins. DJ001 compound inhibition was calcu-
lated as percentage inhibition of the enzymatic activity compared with control.
Pharmacokinetic study for DJ001. PK studies for DJ001 were performed at
Cyprotex (Study Number CYP1426-R1) under non-good laboratory practice
conditions. Mice were subcutaneously injected with a single dose of 5 mg/kg DJ001
(in 10% DMSO, 40% phosphate-buffered saline (PBS), 50% polyethylene glycol
and plasma samples were collected at 0.08, 0.25, 0.5, 1, 2, 4, 8, and 24 h. Samples
were crashed with three volumes of methanol and analytical internal standard
(propranolol). Supernatant was subjected to liquid chromatography-mass spec-
trometry/mass spectrometry (MS/MS) using an acetonitrile-water gradient system
and electrospray ionization in multiple reaction monitoring mode for MS detec-
tion. All plasma samples were compared with an internal calibration curve pre-
pared in mouse blank plasma.
Proximity ligation assay. A PLA assay was performed by using the Duolink In
Situ Red Starter Kit (Millipore Sigma) to detect the binding between PTPσ and
p250GAP proteins. BM KSL cells from C57BL/6 mice were sorted by fluorescence-
activated cell sorting and then plated onto fibronectin pre-coated chamber slides
overnight. The next day, cells were treated with 1 μg/mL DJ001 or vehicle (equal
volume of DMSO) for 1 h at 37 °C. Cells were then fixed with 4% paraformalde-
hyde (PFA) for 20 min. The slides were blocked with Duolink blocking solution
and incubated with rabbit anti-ARHGAP32 polyclonal antibody (Bioss Antibodies,
#bs-9296R, 1:50 dilution) and goat anti-PTPσ (K-19) polyclonal antibody (Santa
Cruz Biotechnology, #sc-10873, 1:50) overnight at 4 °C. Cells were imaged using a
Leica SP8 Confocal Microscope equipped with a ×63 objective lens. A white light
laser set to 580 nm was used to excite dsRed and a UV laser was used to excite 4′,6-
diamidino-2-phenylindole (DAPI). Analysis was performed using the spots
detection function in IMARIS 9.0.2 (Bitplane).
p250GAP phospho-tyrosine sandwich ELISA. Clear, pre-blocked Protein A-
coated Microtiter wells (Fisher Scientific, #15132) were incubated with ARHGAP32
polyclonal antibody (Bioss, #bs-9296R, 1:500) in antibody dilution buffer (150 mM
NaCl, 25 mM HEPES pH 7.2, 0.5% bovine serum albumin, 0.05% Tween 20) for 3 h
at room temperature (RT). Subsequently, the plate was washed three times and
phosphorylated p250GAP from BM lin− cell lysate was added to each well. BM
lin− cells were collected in NP40 buffer (ThermoFisher Scientific; FNN0021)
supplemented with 1× complete, Mini, EDTA-free Protease Inhibitor Cocktail
(Sigma Aldrich; 4693159001) and 1× PhosSTOP (Sigma Aldrich; 4906845001).
Following incubation for 2 h at 4 °C, the plate was completely emptied (without
washing) and exposed to 50 μL of a fixation solution (0.5% formaldehyde in 300
mM NaCl, 20 mM sodium phosphate buffer, pH 7) for 10 min. The plate-bound,
phosphorylated p250GAP was measured by a specific anti-phospho-tyrosine
peroxidase-coupled antibody (Sigma Aldrich, #A5964-1VL, 1:500) in antibody
dilution buffer. Incubation was for 1 h at RT. Peroxidase activity was measured by a
Tecan Infinity plate reader using BM Chemiluminescence ELISA Substrate (Sigma
Aldrich, #11582950001).
G-LISA activation assays. The RAC1-GTP, RHOA-GTP, and CDC42-GTP
activation levels in BM lin− cells were measured using a colorimetric-based RAC1-,
RHOA-, and CDC42 G-LISA Activation Assay Kit (Cytoskeleton, Inc.). BM cells
from femurs and tibias were isolated from 12-week-old Ptprs+/+ and Ptprs−/−
mice. Cells were then depleted of lineage-committed cells with Direct Lineage Cell
Depletion Kit (Miltenyi Biotec, #130-110-470; 1:5). The BM lin− cell fraction was
then serum starved in Iscove’s modified Dulbecco’s medium (IMDM) and treated
with either vehicle (equal amount of DMSO) or 1 μg/mL DJ001 for 10 min at 37 °C.
After treatment, cells were washed with ice-cold PBS and then placed in lysis buffer
supplemented with protease inhibitor. Lysate concentrations were measured by
PierceTM BCA Protein Assay Kit (ThermoFisher Scientific). G-LISA was performed
according to the manufacturer’s instructions. Briefly, 12.5 μg of lysates was added
to a GTP-binding protein pre-coated plate and active RAC1-GTP, RHOA-GTP, or
CDC42-GTP levels were measured at 490 nm using a PowerWave XS2 microplate
reader (BioTek).
Lentivirus-mediated shRNA silencing. Rac1 CDS-targeting- and Bcl2l1 CDS-
targeting shRNA in lentiviral plasmid (TRCN0000310888 and TRCN0000004685)
and control shRNA (SHC216V) were purchased from Sigma Aldrich. For viral
production, 293T cells were transfected with lentiviral gag/pol and VSV-G
(courtesy of Donald Kohn, UCLA) and the lentiviral plasmids, at a ratio of 2.2: 1.2:
3.3 (in [μg], gag/pol:VSVG:Plasmid) using Lipofectamine 3000 and P300 Enhancer.
Viral particles were collected after 24 h and 48 h. One milliliter of viral supernatant
was used to infect 0.75 × 106 BM lin− cells. Infected cells were collected the next
day and irradiated with 300 cGy followed by treatment with or without 1 μg/mL
DJ001, prior to CFC assay.
Immunofluorescence microscopy. Lab-Tek chamber slides were coated with
fibronectin (25 µg/mL, Millipore Sigma #341635). Sorted BM KSL cells (1 × 104)
were resuspended in 200 µL TSF media and added to each of the pre-coated wells
and incubated overnight (37 °C/5% CO2). The next day, cells were serum starved
for 30 min and then stimulated with DJ001 (1 µg/mL), EHT1864 (6 µg/mL), or
equal volumes of DMSO for 5 min. Cells were washed once with PBS and fixed
with 4% PFA for 10 min. Cells were permeabilized with 0.5% Triton/PBS (PRM)
for 30 min and then blocked with 5% fetal bovine serum (FBS)/PRM for 1 h. The
slide was then incubated with a phospho-ERK1/2 primary antibody (Cell Signaling,
#4377, 1:200) for 1 h. The wells were washed three times and then incubated with a
donkey anti-rabbit Alexa Fluor 488 secondary antibody (Thermo Fischer, #A21206,
1:200) at a 1:200 concentration for 1 h. The slide was washed three times and
mounted with ProLong Gold Antifade Reagent with DAPI. Cells were imaged
using a ×63 objective on a Zeiss Axio Imager M2 widefield fluorescence microscope
with all microscope settings derived from imaging a secondary only control. Data
were analyzed using Fiji (ImageJ). Briefly, the cell outline was identified by
threshold levels and the mean fluorescence intensity within the cell area was
quantified.
Flow cytometric analysis. Femurs and tibiae were collected from killed C57BL/6 or
Ptprs−/− mice and flushed with IMDM containing 10% FBS and 1%
penicillin–streptomycin for BM cells. PB was collected through sub-mandibular
puncture. Cells were filtered through a 40 μM strainer and then treated with ACK
lysis buffer (Sigma Aldrich) before antibody staining for flow cytometry. For KSL and
CD150+CD48−KSL cell analysis, BM cells were stained with allophycocyanin (APC)-
and Cy7-conjugated anti-mouse Sca1 (BD Biosciences, #560654, 1:100), phycoery-
thrin (PE)-conjugated anti-mouse c-kit (BD Biosciences, #553355, 1:100), V450
lineage cocktail (BD Biosciences, 561301, 1:10), Alexa Fluor 488-conjugated anti-
mouse CD48 (BioLegend, #103414, 1:100), and Alexa Fluor 647-conjugated anti-
mouse CD150 (Biolegend, #115918, 1:100) antibodies. For MEP, CMP, GMP, and
CLP cell analysis, BM cells were stained with APC-Cy7-conjugated anti-mouse Sca1
(BD Biosciences, #560654, 1:100), PE-conjugated anti-mouse ckit (BD Biosciences,
#553355, 1:100), V450 lineage cocktail (BD Biosciences, #561301; 1:10), Alexa Fluor
488-conjugated anti-mouse CD127 (BD Biosciences, #561533, 1:100), Alexa Fluor
647-conjugated anti-mouse CD34 (BD Biosciences, #560230; 1:100), and BV605-
conjugated anti-mouse CD16/32 antibodies (BD Biosciences, #563006; 1:100). For
donor engraftment analysis in transplanted mice, PB or BM cells were stained with
BV605-conjugated anti-mouse CD45.2 (BioLegend, #109841, 1:100), fluorescein iso-
thiocyanate (FITC)-conjugated anti-mouse CD45.1 (BD Biosciences, #553775, 1:100),
PE-conjugated anti-mouse Mac-1 (BD Biosciences, #557397, 1:100) and anti-mouse
Gr1 (BD Biosciences, #553128, 1:100), V450-conjugated anti-mouse CD3 (BD Bios-
ciences, #561389, 1:100), and APC-Cy7-conjugated anti-mouse B220 (BD Biosciences,
552094, 1:100) antibodies.
Intracellular flow cytometric analysis was performed on irradiated (300 cGy) or
non-irradiated, sorted KSL cells after treatment with 1 μg/mL DJ001 or control
(equal volumes of DMSO) for 24 h. At 24 h after irradiation, cells were fixed with
4% PFA for 10 min, followed by permeabilization using 0.25% saponin in PBS.
Cells were washed again and stained with antibody at the recommended
concentrations for 30 min at RT. Intracellular antibodies and phospho-flow
antibodies used were as follows: FITC-conjugated anti-BCL-XL (Abcam, #26148,
1:100), active RAC1-GTP antibody (NewEast Biosciences, #26903, 1:100) and anti-
PAK1 (phospho S144)+ PAK2 (phospho S141)+ PAK3 (phospho S154) antibody
(Abcam, #40795, 1:100), and FITC-conjugated goat anti-rabbit IgG H&L (Abcam,
#97050, 1:200).
Gene expression analysis. For all studies, RNA was isolated using the Qiagen
RNeasy micro kit (Qiagen). RNA was reverse transcribed using the High-Capacity
cDNA Reverse Transcription Kit (ThermoFisher Scientific) and was then used for
quantitative PCR with SYBR Select Master Mix (Life Technologies). Values were
normalized to housekeeping gene Gapdh/GAPDH and given as ΔΔCt values nor-
malized to media-treated, non-irradiated BM KSL cells (2(−ΔΔC(T)) method)67.
Survival studies. For survival studies, 10-week-old female C57BL/6 mice were
irradiated with 750 cGy TBI, which is lethal for ~50% of C57BL/6 mice by day+ 30
(LD50/30), using a Shepherd Cesium-137 irradiator. Twenty four hours post
irradiation, mice were administered daily subcutaneous injections of 5 mg/kg
DJ001 or DJ009, or vehicle in a volume of 100 μL for 10 days. DJ001 or DJ009
injections were prepared in PBS, 0.5% Tween 80, and 10% DMSO. Corresponding
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vehicle injections contained PBS, 10% DMSO, and 0.5% Tween 80. PB complete
blood counts were measured using a Hemavet 950 instrument (Drew Scientific) at
day+ 10 post irradiation. For hematopoietic analysis, BM cells were collected at
day+ 10 post irradiation. To study whether DJ001 increased survival rates through
activation of RAC signaling, the RAC inhibitor, EHT1864 (Selleckchem), was
dissolved in PBS and administered intraperitoneally, 40 mg/kg every other day, to
750 cGy-irradiated mice until day+ 10.
Chemotherapy model. Ten-week-old female C57BL/6 mice received a single tail
vein injection of 250 mg/kg 5FU in 100 μL PBS. Two hours post 5FU injection,
mice were administered daily subcutaneous injections of 5 mg/kg (100 μg per
mouse) DJ001 or vehicle in a volume of 100 μL for 8 days. DJ001 injections were
prepared in PBS, 50% PEG-400, and 10% DMSO. Corresponding vehicle injections
contained PBS, 50% PEG-400, and 10% DMSO. Retro-orbital blood was collected
on day+ 8, + 11, and+ 14 after 5FU treatment with capillary pipettes (Fisher
Scientific). Complete blood counts were measured using a Hemavet 950 instrument
(Drew Scientific).
Cytokine analysis. For in vitro cytokine measurements, 3.5 × 104 BM KSL cells
were irradiated with 300 cGy and cultured in TSF media with and without 1 μg/mL
DJ001. Non-irradiated KSL cells were cultured in TSF media with and without 1
μg/mL DJ001. At 12 h of culture, culture supernatants were collected for analysis.
For in vivo cytokine measurements, adult C57BL/6 mice were irradiated with 750
cGy TBI and then treated with 5 mg/kg of DJ001 or vehicle, subcutaneously, from
day+ 1 to day+ 5. Non-irradiated mice received the identical regimen of 5 mg/kg
DJ001 or vehicle for 5 days. Mice were killed and BM cells were collected into
IMDM. Cells were pelleted and the BM supernatant was collected and sent to the
UCLA Immune Assessment Core for cytokine analysis. All samples were tested on
a mouse 32-plex Cytokine/Chemokine panel platform from EMD Milipore using
Luminex’s xMAP® immunoassay technology (Luminex, Inc.). In addition, the
following cytokine levels were assessed by solid-phase ELISA assay according to the
manufacturer’s description: CXCL12 (R&D Systems), SCF (R&D Systems),
Thrombopoietin (TPO) (R&D Systems), PTN (Biomatik), DKK1 (R&D Systems),
and EGF (R&D Systems).
In vivo BrdU incorporation analysis. For BrdU incorporation analysis in BM KSL
cells in vivo, adult C57Bl/6 mice were irradiated with 750 cGy TBI and treated with
5 mg/kg DJ001 or vehicle daily from day+ 1 to day+ 10. On day+ 10, mice were
injected intraperitoneally with 2 mg BrdU (BD Biosciences). Sixteen hours later,
BM cells were collected and stained with anti-BrdU FITC (BD Biosciences,
#557891, 1:50), APC-Cy7-conjugated anti-Sca1 (BD Biosciences, #560654, 1:100),
PE-conjugated anti-c-kit (BD Biosciences, #553355, 1:100), and V450 lineage
cocktail (BD Biosciences, #561301, 1:10). We repeated this BrdU incorporation
analysis on donor CD45.2+ cells at day+ 7 and day+ 21 following competitive
transplantation into recipient CD45.1+ mice.
Apoptosis assay and cell cycle analysis. Eight- to ten-week-old female C57BL/6
mice were irradiated with 500 cGy TBI followed by subcutaneous injections of 5
mg/kg DJ001 or vehicle, or 5 mg/kg DJ001 plus 40 mg/kg EHT1864. Twenty four
hours after irradiation, mice were killed to collect BM cells for Annexin V
apoptosis analysis. BM cells were stained with APC-Cy7-conjugated anti-mouse
Sca1 (BD Biosciences, #560654, 1:100), PE-conjugated anti-ckit (BD Biosciences,
#553355, 1:100), and V450 lineage cocktail (BD Biosciences, #561301, 1:10)
antibodies for 30 min at 4 °C. Cells were then resuspended in 1× Annexin V
binding buffer and then stained with FITC-conjugated anti-Annexin V antibody
(BD Biosciences, #556547,1:50) and 7AAD antibody (BD Biosciences, #559925,
1:40)68. For in vitro human BM cell apoptosis assays, isolated human BM
CD34+ cells were plated into 96-well plates and then irradiated with 300 cGy.
Immediately after irradiation, cells were treated with 5 μg/mL DJ001 or vehicle
for 24 h and then collected for Annexin V cell apoptosis analysis. For cell cycle
analysis, BM KSL cells were irradiated at 300 cGy and then treated with 1 μg/mL
DJ001 or vehicle for 36 h. Subsequently, cells were resuspended in 200 μL of PBS,
fixed with 1 mL of ice-cold fixation solution (0.25% Saponin, 2.5% PFA, 2% fetal
calf serum (FCS) in PBS), and incubated for 30 min on ice. Cells were washed in
Saponin buffer (0.25% Saponin, 2% FCS in PBS) and resuspended in 200 μL of
Saponin buffer containing 20 μL of FITC-conjugated anti-Ki67 antibody (BD
Biosciences, #556026, 1:10) and 1 μL of RNase (Qiagen, #19101, 100 mg/mL).
After 30 min of incubation, cells were washed in Saponin buffer and resuspended
for flow analysis in 200 μL of Saponin buffer containing 5 μL 7AAD (BD Bios-
ciences, #559925, 1:40).
Isolation of BM HSCs. BM cells were first treated with ACK lysis buffer (Sigma
Aldrich) and lineage-committed cells were removed using a Direct Lineage Cell
Depletion Kit (Miltenyi Biotec, #130-110-470, 1:5). Lin− cells were stained with
APC-Cy7-conjugated anti-mouse Sca1 (BD Biosciences, #560654, 1:100), PE-
conjugated anti-ckit (BD Biosciences, #553355, 1:100), V450 lineage cocktail
(BD Biosciences, #561301, 1:10), and FITC-conjugated anti-CD34 (BD
Biosciences, #553733, 1:100) antibodies. Sterile cell sorting was conducted on a
BD FACS-Aria cytometer. Purified KSL cells and CD34−c-kit+sca-1+Lin−
(CD34−KSL) cells were collected into IMDM (Life Technologies)+ 10% FBS+
1% penicillin–streptomycin.
CFC assays and HSC competitive repopulation assays. CFC assays (colony-
forming unit-granulocyte monocyte), burst-forming unit-erythroid, and CFU-
GEMM were performed using MethoCult GF M3434 (Stemcell Technologies)6. For
all in vitro assays, BM CD34−KSL cells, KSL cells, and Lin− cells were cultured in
TSF media (IMDM, 10% FBS, 1% pen-strep, 20 ng/mL recombinant mouse TPO,
125 ng/mL recombinant mouse SCF, 50 ng/mL recombinant mouse Flt3 ligand).
Recombinant mouse SCF, Flt3 ligand, and TPO were purchased from R&D Sys-
tems. For competitive repopulation assays, BM cells were isolated from donor
10–12-week-old female CD45.2+ mice. Recipient 10-week-old female CD45.1+ B6.
SJL mice were irradiated with 950 cGy TBI using a Cs137 irradiator and donor BM
cells were administered via tail vein injection along with a competing dose of 1 ×
105 non-irradiated host BM cells. Multilineage donor hematopoietic cell engraft-
ment was measured in the PB by flow cytometry69.
Transendothelial migration assay. For the transendothelial migration assay,
VeraVecTM mouse spleen ECs (Angiocrine Biosciences) were cultured to con-
fluence in 8 µM pore transwells (Corning Incorporated). Transwells were then
seeded with 50,000 sorted BM KSL cells in IMDM with 10% FBS, 1% pen-strep, 20
ng/mL TPO, 125 ng/mL SCF, and 50 ng/mL Flt3 ligand with or without 1 µg/mL of
DJ001. SDF-1, 500 ng/mL (R&D Systems), was added to the bottom chamber of the
transwell. At 18 h post incubation, cells in the bottom chamber were collected and
cell counts were performed.
Homing study. Sorted BM sca-1+lin− cells (100,000) from DsRed+ mice were
transplanted into lethally irradiated (950 cGy) recipient C57BL/6 mice followed by
subcutaneous treatment of 5 mg/kg DJ001 or vehicle × 1 dose. At 18 h post
transplantation, BM cells were collected from the recipient mice and were analyzed
for percentages of DsRed+ cells in the BM17.
Human BM cultures and human BM transplantation assays. Human BM
mononuclear cells were purchased from AllCells. Cryopreserved human BM cells
were recovered in IMDM+ 10% FBS+ 1% penicillin–streptomycin and then posi-
tively selected for CD34+ stem/progenitor cells by using CD34 MicroBead Kit
(Miltenyi Biotec, #130-046-702, 1:5). CD34+ cells were cultured in human TSF media
(IMDM, 10%FBS, 1% pen-strep, 20 ng/mL recombinant human TPO, 125 ng/mL
recombinant human SCF, 50 ng/mL recombinant human Flt3 ligand (R&D Systems).
The progeny of 2 × 105 irradiated, human BM CD34+ cultured for 36 h and treated
with DJ001 at 5 μg/mL, were transplanted via tail vein injection into 10–12-week-old
NSG mice preconditioned with 275 cGy TBI. Multilineage donor hematopoietic cell
engraftment was monitored in the PB and BM by flow cytometry20. The PB or BM
cells were stained with BV605-conjugated anti-mouse CD45 (BioLegend, #103139,
1:100), AF647-conjugated anti-human CD34 (BioLegend, #343618, 1:100), FITC-
conjugated anti-human CD33 (BD Biosciences, #555626, 1:100), V450-conjugated
anti-human CD45 (BD Biosciences, #560368, 1:100), APC-conjugated anti-human
CD3 (BD Biosciences, #555342, 1:100), and APC-Cy7-conjugated anti-human CD19
(BD Biosciences, #557791, 1:100) antibodies.
In silico molecular docking studies. Molecular docking of DJ001, (Z)-isomer, to
PTPσ (PDB ID: 2FH7) was carried out by AutoDock Vina, in which the Iterated
Local Search Globule Optimizer was applied as optimization algorithm70. Each
structure of ligand was prepared in Maestro 10.5 (Schroedinger, LLC) and mini-
mized with the OPLS_2005 force field. All hydrogen atoms were added to each
protein and ligand to be docked and each coordinate file of protein and ligand was
generated as PDBQT file using AutoDockTools-1.5.6. A grid box for binding site
was set as 18 Å in the three dimensions (x, y, and z) that covered the catalytic site of
the protein or 40 Å in the three dimensions for allosteric binding site. The box had
1.0 Å grid spacing and centered at the geometric center of the protein. In each
docking experiment, the best binding mode was selected according to the binding
affinity calculated by the scoring function in AutoDock Vina. Docking results were
analyzed with PyMOL (Schroedinger LLC, NY) and visualized by VMD 1.9.2
(UIUC, IL).
Statistical analysis. GraphPad Prism 6.0 was used for all statistical analyses. All
data were checked for normal distribution and similar variance between groups.
Data were derived from multiple independent experiments from distinct mice or
cell culture plates. Sample sizes for in vitro studies were chosen based on observed
effect sizes and SEs from prior studies. For all animal studies, a power test was used
to determine the sample size needed to observe a twofold difference in means
between groups with 0.8 power. A two-tailed Student’s t-test was utilized for all
comparison, except where otherwise noted in the figure legends. All animal studies
were performed using sex- and age-matched animals, with wild-type littermates as
controls. Animal studies were performed without blinding of the investigator.
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Values are reported as means ± SEM, unless stated otherwise. Results were con-
sidered significant when P < 0.05.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that all data supporting the findings of this study are available within
the article and its Supplementary Information files or from the corresponding author
upon reasonable request. The source data underlying Figs. 1b, c, e, 2, 3, 4, and 5 are
provided as a Source Data File.
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